Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics

Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864

Goodman & Gilman's The Pharmacological Basis of Therapeutics

Brunton, L. L. (1985) · Cited by 7,321

Goodman and Gilman's the Pharmacological Basis of Therapeutics

Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,796

Inflammation and Alzheimer’s disease

Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514

Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291

Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160

Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012

Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease

Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530

Immune attack: the role of inflammation in Alzheimer disease

Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134

Clearance systems in the brain—implications for Alzheimer disease

Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.119 · Cited by 1,678

Systemic infections and inflammation affect chronic neurodegeneration

Perry, V. H., Cunningham, C., & Holmes, C. (2007) · Nature Reviews Immunology · doi:10.1038/nri2015 · Cited by 1,027

Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome

Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780

Immune activation in brain aging and neurodegeneration: too much or too little?

Lucin, K. M., & Wyss-Coray, T. (2009) · Neuron · doi:10.1016/j.neuron.2009.08.039 · Cited by 679

The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective

Shaftel, S. S., Griffin, W. S. T., & O'Banion, M. K. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-7 · Cited by 565

Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo

Klyubin, I., Walsh, D. M., Lemere, C. A., Cullen, W. K., Shankar, G. M., Betts, V., Spooner, E. T., Jiang, L., Anwyl, R., Selkoe, D. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1234 · Cited by 489

Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β

Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage.

Wilcock, D. M., Rojiani, A. M., Rosenthal, A., Subbarao, S., Freeman, M. J., Gordon, M. N., & Morgan, D. (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-24 · Cited by 392

Inflammatory Response in the Hippocampus of PS1M146L/APP751SLMouse Model of Alzheimer's Disease: Age-Dependent Switch in the Microglial Phenotype from Alternative to Classic

Jimenez, S., Baglietto-Vargas, D., Caballero, C., Moreno-Gonzalez, I., Torres, M., Sanchez-Varo, R., Ruano, D., Vizuete, M., Gutierrez, A., & Vitorica, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3024-08.2008 · Cited by 383

Il10 Deficiency Rebalances Innate Immunity to Mitigate Alzheimer-Like Pathology

Guillot-Sestier, M.-V., Doty, K. R., Gate, D., Rodriguez, J., Leung, B. P., Rezai-Zadeh, K., & Town, T. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.068 · Cited by 363

Therapeutic approaches to Alzheimer's disease

Klafki, H., Staufenbiel, M., Kornhuber, J., & Wiltfang, J. (2006) · Brain · doi:10.1093/brain/awl280 · Cited by 362

Immunology and immunotherapy of Alzheimer's disease

Weiner, H. L., & Frenkel, D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1843 · Cited by 335

Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition

Wilcock, D. M., Rojiani, A. M., Rosenthal, A., Levkowitz, G., Subbarao, S., Alamed, J., Wilson, D. H., Wilson, N., Freeman, M. J., Gordon, M. N., et al. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1090-04.2004 · Cited by 302

Microglia actions in Alzheimer's disease

Prokop, S., Miller, K. R., & Heppner, F. L. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1182-x · Cited by 291

Inflammatory components in human Alzheimer’s disease and after active amyloid-β42 immunization

Zotova, E., Bharambe, V., Cheaveau, M., Morgan, W., Holmes, C., Harris, S., Neal, J. W., Love, S., Nicoll, J. A. R., & Boche, D. (2013) · Brain · doi:10.1093/brain/awt210 · Cited by 272

Microglia and neuroprotection: From in vitro studies to therapeutic applications

Polazzi, E., & Monti, B. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.009 · Cited by 269

Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy

Zotova, E., Nicoll, J. A. R., Kalaria, R. N., Holmes, C., & Boche, D. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt24 · Cited by 269

Active and passive immunotherapy for neurodegenerative disorders

Brody, D. L., & Holtzman, D. M. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.31.060407.125529 · Cited by 250

Persistent Amyloidosis following Suppression of Aβ Production in a Transgenic Model of Alzheimer Disease

Jankowsky, J. L., Slunt, H. H., Gonzales, V., Savonenko, A. V., Wen, J. C., Jenkins, N. A., Copeland, N. G., Younkin, L. H., Lester, H. A., Younkin, S. G., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020355 · Cited by 237

β-Amyloid Deposition and Functional Impairment in the Retina of the APPswe/PS1ΔE9 Transgenic Mouse Model of Alzheimer’s Disease

Perez, S. E., Lumayag, S., Kovacs, B., Mufson, E. J., & Xu, S. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2384 · Cited by 236

Immunotherapy for Alzheimer’s disease: Key Symposium: Immunotherapy for Alzheimer’s disease

Morgan, D. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02315.x · Cited by 225

Neuronal Aggregates: Formation, Clearance, and Spreading

Lim, J., & Yue, Z. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.02.002 · Cited by 226

Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease

Farfara, D., Lifshitz, V., & Frenkel, D. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00314.x · Cited by 216

Dnr1 mutations cause neurodegeneration in Drosophila by activating the innate immune response in the brain

Cao, Y., Chtarbanova, S., Petersen, A. J., & Ganetzky, B. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306220110 · Cited by 214

The immunology of neurodegeneration

Czirr, E., & Wyss‐Coray, T. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58656 · Cited by 218

Updates in Alzheimer's disease: from basic research to diagnosis and therapies

Liu, E., Zhang, Y., & Wang, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00432-x · Cited by 241

Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives

Wang, Y., Zhou, H., & Zhou, X. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.08.004 · Cited by 204

Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice

Brendza, R. P., Bacskai, B. J., Cirrito, J. R., Simmons, K. A., Skoch, J. M., Klunk, W. E., Mathis, C. A., Bales, K. R., Paul, S. M., Hyman, B. T., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23269 · Cited by 190

Dynamic Complexity of the Microglial Activation Response in Transgenic Models of Amyloid Deposition: Implications for Alzheimer Therapeutics

Morgan, D., Gordon, M. N., Tan, J., Wilcock, D. M., & Rojiani, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000178444.33972.e0 · Cited by 176

Imaging Microglial Activation During Neuroinflammation and Alzheimer’s Disease

Venneti, S., Wiley, C. A., & Kofler, J. (2008) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-008-9142-2 · Cited by 172

Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears β-amyloid in a mouse model of Alzheimer disease

Frenkel, D., Maron, R., Burt, D. S., & Weiner, H. L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23241 · Cited by 189

Microglia Demonstrate Age-Dependent Interaction with Amyloid-β Fibrils

Floden, A. M., & Combs, C. K. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101014 · Cited by 166

Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis

Kim, J., Eltorai, A. E. M., Jiang, H., Liao, F., Verghese, P. B., Kim, J., Stewart, F. R., Basak, J. M., & Holtzman, D. M. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20121274 · Cited by 160

Clinical aspects of inflammation in Alzheimer's disease

Rosenberg, P. B. (2005) · International Review of Psychiatry · doi:10.1080/02646830500382037 · Cited by 158

Immunotherapy for Alzheimer's disease

Gélinas, D. S., Silva, K. D., Fenili, D., George‐Hyslop, P. S., & McLaurin, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404866101 · Cited by 161

New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease

Fuller, J. P., Stavenhagen, J. B., & Teeling, J. L. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00235 · Cited by 154

Deglycosylated Anti-Amyloid-β Antibodies Eliminate Cognitive Deficits and Reduce Parenchymal Amyloid with Minimal Vascular Consequences in Aged Amyloid Precursor Protein Transgenic Mice

Wilcock, D. M., Alamed, J., Gottschall, P. E., Grimm, J., Rosenthal, A., Pons, J., Ronan, V., Symmonds, K., Gordon, M. N., & Morgan, D. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0695-06.2006 · Cited by 155

Time-dependent reduction in Aβ levels after intracranial LPS administration in APP transgenic mice

Herber, D. L., Roth, L. M., Wilson, D. H., Wilson, N., Mason, J. E., Morgan, D., & Gordon, M. N. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.07.007 · Cited by 151

Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models

Busche, M. A., Grienberger, C., Keskin, A. D., Song, B., Neumann, U., Staufenbiel, M., Förstl, H., & Konnerth, A. (2015) · Nature Neuroscience · doi:10.1038/nn.4163 · Cited by 146

Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition

Price, B. R., Sudduth, T. L., Weekman, E. M., Johnson, S. N., Hawthorne, D., Woolums, A. E., & Wilcock, D. M. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01915-0 · Cited by 146

Microglial activation states and their implications for Alzheimer's Disease

Valiukas, Z., Tangalakis, K., Apostolopoulos, V., & Feehan, J. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100013 · Cited by 167

Microglial Activation is Required for Aβ Clearance After Intracranial Injection of Lipopolysaccharide in APP Transgenic Mice

Herber, D. L., Mercer, M., Roth, L. M., Symmonds, K., Maloney, J. L., Wilson, N., Freeman, M. J., Morgan, D., & Gordon, M. N. (2007) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-007-9069-z · Cited by 143

Overexpression of Monocyte Chemotactic Protein-1/CCL2 in β-Amyloid Precursor Protein Transgenic Mice Show Accelerated Diffuse β-Amyloid Deposition

Yamamoto, M., Horiba, M., Buescher, J. L., Huang, D., Gendelman, H. E., Ransohoff, R. M., & Ikezu, T. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62364-4 · Cited by 137

Intracerebroventricular amyloid-β antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice

Thakker, D. R., Weatherspoon, M. R., Harrison, J., Keene, T. E., Lane, D. S., Kaemmerer, W. F., Stewart, G. R., & Shafer, L. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813404106 · Cited by 124

Multiple sclerosis and Alzheimer's disease

Dal Bianco, A., Bradl, M., Frischer, J., Kutzelnigg, A., Jellinger, K., & Lassmann, H. (2008) · Annals of Neurology · doi:10.1002/ana.21240 · Cited by 123

Current therapeutic targets for the treatment of Alzheimer’s disease

Grill, J. D., & Cummings, J. L. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.29 · Cited by 123

Internalized Antibodies to the Aβ Domain of APP Reduce Neuronal Aβ and Protect against Synaptic Alterations

Tampellini, D., Magrané, J., Takahashi, R. H., Li, F., Lin, M. T., Almeida, C. G., & Gouras, G. K. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700373200 · Cited by 118

Robust amyloid clearance in a mouse model of Alzheimer’s disease provides novel insights into the mechanism of amyloid-β immunotherapy

Wang, A., Das, P., Switzer, R. C., Golde, T. E., & Jankowsky, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5077-10.2011 · Cited by 118

Diverse microglial responses after intrahippocampal administration of lipopolysaccharide

Herber, D. L., Maloney, J. L., Roth, L. M., Freeman, M. J., Morgan, D., & Gordon, M. N. (2005) · Glia · doi:10.1002/glia.20272 · Cited by 118

Microglia

Kofler, J., & Wiley, C. A. (2010) · Toxicologic Pathology · doi:10.1177/0192623310387619 · Cited by 122

Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease

Simard, A. R., & Rivest, S. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001809 · Cited by 113

Characterization of different bubble formulations for blood-brain barrier opening using a focused ultrasound system with acoustic feedback control

Bing, C.-C., Hong, Y., Hernandez, C., Rich, M., Cheng, B., Munaweera, I., Szczepanski, D., Xi, Y., Bolding, M. S., Exner, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26330-7 · Cited by 96

Degradation of Alzheimer's amyloid fibrils by microglia requires delivery of ClC-7 to lysosomes

Majumdar, A., Capetillo‐Zarate, E., Cruz, D. L., Gouras, G. K., & Maxfield, F. R. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-09-0745 · Cited by 109

Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: Relevance of Transgenic Mouse Studies to Clinical Trials

Wilcock, D. M., & Colton, C. A. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15404 · Cited by 107

Microglial alterations in human Alzheimer's disease following Aβ42 immunization

Zotova, E., Holmes, C., Johnston, D. A., Neal, J., Nicoll, J. A. R., & Boche, D. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01156.x · Cited by 109

Positron emission tomography and single-photon emission computed tomography in central nervous system drug development

Brooks, D. J. (2005) · NeuroRx · doi:10.1602/neurorx.2.2.226 · Cited by 106

Neuroinflammation in the Aging Down Syndrome Brain; Lessons from Alzheimer's Disease

Wilcock, D. M. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/170276 · Cited by 104

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

Magga, J. M., Puli, L., Pihlaja, R., Kanninen, K. M., Neulamaa, S., Malm, T., Härtig, W., Grosche, J., Goldsteins, G., Tanila, H., et al. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-90 · Cited by 100

Inflammation in transgenic mouse models of neurodegenerative disorders

Schwab, C., Klegeris, A., & McGeer, P. L. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.013 · Cited by 97

Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid

Wilcock, D. M., Jantzen, P. T., Li, Q., Morgan, D., & Gordon, M. N. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.10.020 · Cited by 95

The Role of Macrophage Migration Inhibitory Factor in Alzheimer’s Disease

Bacher, M., Deuster, O., Aljabari, B., Egensperger, R., Neff, F., Jessen, F., Popp, J., Noelker, C., Reese, J. P., Al‐Abed, Y., et al. (2010) · Molecular Medicine · doi:10.2119/molmed.2009.00123 · Cited by 92

Central nervous system inflammation in disease related conditions: Mechanistic prospects

Fung, A., Vizcaychipi, M. P., Lloyd, D. G., Wan, Y., & Ma, D. (2012) · Brain Research · doi:10.1016/j.brainres.2012.01.061 · Cited by 95

Disease-Modifying Therapies in Alzheimer???s Disease

ll, M. H., Berger, T., & Heneka, M. T. (2006) · Drugs · doi:10.2165/00003495-200666160-00004 · Cited by 95

In vivo targeting of antibody fragments to the nervous system for Alzheimer’s disease immunotherapy and molecular imaging of amyloid plaques

Poduslo, J. F., Ramakrishnan, M., Holasek, S. S., Ramı́rez-Alvarado, M., Kandimalla, K. K., Gilles, E. J., Curran, G. L., & Wengenack, T. M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04591.x · Cited by 91

Aβ plaques

Walker, L. C. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3025 · Cited by 113

Proliferation in the Alzheimer Hippocampus Is due to Microglia, Not Astroglia, and Occurs at Sites of Amyloid Deposition

Marlatt, M. W., Bauer, J., Aronica, E., van Haastert, E. S., Hoozemans, J. J. M., Joels, M., & Lucassen, P. J. (2014) · Neural Plasticity · doi:10.1155/2014/693851 · Cited by 83

Microglia and their CX3CR1 signaling are involved in hippocampal- but not olfactory bulb-related memory and neurogenesis

Reshef, R., Kreisel, T., Kay, D. B., & Yirmiya, R. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.04.009 · Cited by 84

Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects

Loeffler, D. A. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230025 · Cited by 90

Synaptic plasticity disruption by amyloid β protein: modulation by potential Alzheimer's disease modifying therapies

Rowan, M. J., Klyubin, I. V., Wang, Q., & Anwyl, R. (2005) · Biochemical Society Transactions · doi:10.1042/bst0330563 · Cited by 83

Magnetic Resonance Imaging of Alzheimer's Pathology in the Brains of Living Transgenic Mice: A New Tool in Alzheimer's Disease Research

Jack, C. R., Marjańska, M., Wengenack, T. M., Reyes, D. A., Curran, G. L., Lin, J., Preboske, G. M., Poduslo, J. F., & Garwood, M. (2007) · The Neuroscientist · doi:10.1177/1073858406295610 · Cited by 76

Clearance of interstitial fluid (ISF) and CSF (CLIC) group—part of Vascular Professional Interest Area (PIA)

Carare, R. O., Aldea, R., Agarwal, N., Bacskai, B. J., Bechman, I., Boche, D., Bu, G., Bulters, D. O., Alt, C., Counts, S., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12053 · Cited by 77

Innate Immunity in Alzheimer’s Disease: A Complex Affair

Guillot‐Sestier, M., & Town, T. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312050008 · Cited by 72

In vivo evidence for microglial activation in neurodegenerative dementia

Cagnin, A., Kassiou, M., Meikle, S. R., & Banati, R. B. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00694.x · Cited by 71

Alzheimer’s amyloid β heterogeneous species differentially affect brain endothelial cell viability, blood‐brain barrier integrity, and angiogenesis

Parodi‐Rullán, R. M., Ghiso, J. A., Cabrera, E., Rostagno, A. A., & Fossati, S. (2020) · Aging Cell · doi:10.1111/acel.13258 · Cited by 71

Biomarkers for early diagnosis of Alzheimer disease: ‘ALZheimer ASsociated gene’– a new blood biomarker?

Jellinger, K. A., Janetzky, B., Attems, J., & Kienzl, E. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00313.x · Cited by 72

Trehalose against Alzheimer's Disease: Insights into a Potential Therapy

Khalifeh, M., Read, M. I., Barreto, G. E., & Sahebkar, A. (2020) · BioEssays · doi:10.1002/bies.201900195 · Cited by 67

Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease

Gasparini, L., Ongini, E., Wilcock, D. M., & Morgan, D. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.12.029 · Cited by 68

Intracranial Injection of Gammagard, a Human IVIg, Modulates the Inflammatory Response of the Brain and Lowers A in APP/PS1 Mice Along a Different Time Course than Anti-A Antibodies

Sudduth, T. L., Greenstein, A. W., & Wilcock, D. M. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1220-13.2013 · Cited by 71

A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease

Agadjanyan, M. G., Petrovsky, N., & Ghochikyan, A. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.1884 · Cited by 65

MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response

Pellerin, K., Rubino, S. J., Burns, J. C., Smith, B. A., McCarl, C., Zhu, J. K., Jandreski, L., Cullen, P. F., Carlile, T. M., Li, A., et al. (2021) · Brain · doi:10.1093/brain/awab231 · Cited by 66

Passive immunotherapy for Alzheimer's disease

Guo, X., Li, Y., Zhang, D., & Zhao, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102192 · Cited by 69

HLA-DR Alleles in Amyloid β-Peptide Autoimmunity: A Highly Immunogenic Role for the DRB1*1501 Allele

Zota, V. E., Nemirovsky, A., Baron, R., Fisher, Y., Selkoe, D. J., Altmann, D. M., Weiner, H. L., & Monsonego, A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900620 · Cited by 60

Brain aging and garbage cleaning

Gordleeva, S., Игоревич, К. О., Ivanchenko, M., Zaikin, A. A., & Franceschi, C. (2020) · Seminars in Immunopathology · doi:10.1007/s00281-020-00816-x · Cited by 65

Review: Experimental manipulations of microglia in mouse models of Alzheimer's pathology: activation reduces amyloid but hastens tau pathology

Lee, D. C., Rizer, J., Hunt, J. B., Selenica, M. ‐. B., Gordon, M. N., & Morgan, D. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12002 · Cited by 57

Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence

Wilcock, D. M., Morgan, D., Gordon, M. N., Taylor, T. L., Ridnour, L. A., Wink, D. A., & Colton, C. A. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-115 · Cited by 58

Influence of Nanobubble Concentration on Blood–Brain Barrier Opening Using Focused Ultrasound Under Real-Time Acoustic Feedback Control

Cheng, B., Bing, C., Xi, Y., Shah, B., Exner, A. A., & Chopra, R. (2019) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2019.03.016 · Cited by 58

Minocycline reduces engraftment and activation of bone marrow‐derived cells but sustains their phagocytic activity in a mouse model of Alzheimer's disease

Malm, T., Magga, J. M., Kuh, G. F., Vatanen, T., Koistinaho, M., & Koıstınaho, J. (2008) · Glia · doi:10.1002/glia.20726 · Cited by 56

Mechanisms of Aβ Plaque Clearance following Passive Aβ Immunization

Morgan, D. (2005) · Neurodegenerative Diseases · doi:10.1159/000090366 · Cited by 52

Immune complex formation impairs the elimination of solutes from the brain: implications for immunotherapy in Alzheimer’s disease

Carare, R. O., Teeling, J. L., Hawkes, C. A., Püntener, U., Weller, R. O., Nicoll, J. A. R., & Perry, V. H. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-48 · Cited by 51

Intramuscular delivery of a single chain antibody gene reduces brain Aβ burden in a mouse model of Alzheimer's disease

Wang, Y., Pollard, A., Zhong, J., Dong, X., Wu, X., Zhou, H., & Zhou, X. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.06.013 · Cited by 51

Neuroinflammation in Plaque and Vascular β-Amyloid Disorders: Clinical and Therapeutic Implications

Eikelenboom, P., Veerhuis, R., Familian, A., Hoozemans, J. J. M., van Gool, W. A., & Rozemüller, A. J. M. (2008) · Neurodegenerative Diseases · doi:10.1159/000113699 · Cited by 50

Widespread brain distribution and activity following i.c.v. infusion of anti‐β‐secretase (BACE1) in nonhuman primates

Yadav, D. B., Maloney, J. A., Wildsmith, K. R., Fuji, R. N., Meilandt, W. J., Solanoy, H., Lu, Y., Peng, K., Wilson, B., Chan, P., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14021 · Cited by 49

Stimulation of Sigma Receptors with Afobazole Blocks Activation of Microglia and Reduces Toxicity Caused by Amyloid-β25–35

Behensky, A. A., Yasny, I. E., Shuster, A. M., Середенин, С. Б., Petrov, A. V., & Cuevas, J. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208348 · Cited by 50

Intracranial administration of deglycosylated C-terminal-specific anti-Aβ antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice

Carty, N., Wilcock, D. M., Rosenthal, A., Grimm, J., Pons, J., Ronan, V., Gottschall, P. E., Gordon, M. N., & Morgan, D. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-11 · Cited by 50

Solanezumab for Alzheimer's disease

Samadi, H., & Sultzer, D. L. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.578573 · Cited by 48

Minocycline attenuates Aβ oligomers-induced pro-inflammatory phenotype in primary microglia while enhancing Aβ fibrils phagocytosis

El‐Shimy, I. A., Heikal, O. A., & Hamdi, N. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.10.024 · Cited by 48

Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice

MORGAN, D. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.03.017 · Cited by 46

A limited role for microglia in antibody mediated plaque clearance in APP mice

Garcı́a-Alloza, M., Ferrara, B. J., Dodwell, S. A., Hickey, G. A., Hyman, B. T., & Bacskai, B. J. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.07.019 · Cited by 47

A Changing Perspective on the Role of Neuroinflammation in Alzheimer's Disease

Wilcock, D. M. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/495243 · Cited by 48

Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation

Wilcock, D. M., DiCarlo, G., Henderson, D., Jackson, J., Clarke, K., Ugen, K. E., Gordon, M. N., & Morgan, D. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03745.2003 · Cited by 232

A limited role for microglia in antibody mediated plaque clearance in APP mice

Garcı́a-Alloza, M., Ferrara, B. J., Dodwell, S. A., Hickey, G. A., Hyman, B. T., & Bacskai, B. J. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.07.019 · Cited by 47

The Role of Microglia in Antibody-Mediated Clearance of Amyloid-Beta from the Brain

Morgan, D. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601821 · Cited by 58

Mechanisms of ß-Amyloid Clearance by Anti-Aß Antibody Therapy

Wilcock, D. M. (2004) · Digital Commons - University of South Florida (University of South Florida)

Anti-Aβ immunotherapy-mediated amyloid clearance attenuates microglial activation without inducing exhaustion at residual plaquesPreprint

de Weerd, L., Hummel, S., Müller, S. A., Paris, I., Sandmann, T., Eichholtz, M., Gröger, R., Englert, A. L., Wagner, S., Ha, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.10.645950